CuraTeQ Biologics Reports Positive Phase 3 Results for BP11 Biosimilar to Xolair®
MM Desk
13 April, 2026
CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has announced positive